Your browser doesn't support javascript.
loading
Utilisation of the ESMO-MCBS in practice of HTA.
Wild, C; Grössmann, N; Bonanno, P V; Bucsics, A; Furst, J; Garuoliene, K; Godman, B; Gulbinovic, J; Jones, J; Pomorski, M K; Emprechtinger, R.
Afiliação
  • Wild C; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
  • Grössmann N; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
  • Bonanno PV; Independent Pharmaceutical Consultant, Mellieha, Malta.
  • Bucsics A; Department of Finance, University of Vienna, Austria.
  • Furst J; Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
  • Garuoliene K; Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
  • Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Gulbinovic J; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Jones J; Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
  • Pomorski MK; Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
  • Emprechtinger R; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.
Ann Oncol ; 27(11): 2134-2136, 2016 11.
Article em En | MEDLINE | ID: mdl-27502718
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Avaliação da Tecnologia Biomédica / Oncologia Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Avaliação da Tecnologia Biomédica / Oncologia Idioma: En Ano de publicação: 2016 Tipo de documento: Article